Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 6/20 | 0.53 |
| ▸ | CTSL | P07711 | 4/20 | 0.53 |
| ▸ | CTSB | P07858 | 3/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 1/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14254901 | 0.91 | SIRT2 (0.55) | CTSKSYKCTSSCTSLCTSB | |
| SCHEMBL8432281 | 0.91 | KLK5 (0.59) | CTSKSYKCTSSCTSLCTSB | |
| SCHEMBL14037216 | 0.89 | CTSK (0.53) | CTSKSYKCTSSCTSLCTSB | |
| SCHEMBL17756116 | 0.89 | CTSK (0.53) | CTSKSYKCTSSCTSLCTSB | |
| SCHEMBL29398102 | 0.89 | SYK (0.57) | CTSKSYKCTSSCTSLCTSB | |
| SCHEMBL2775895 | 0.89 | PPARA (0.57) | CTSKSYKCTSSCTSLCTSB | |
| SCHEMBL1143898 | 0.89 | PPARA (0.57) | CTSKSYKCTSSCTSLCTSB | |
| SCHEMBL478289 | 0.89 | PPARA (0.57) | CTSKSYKCTSSCTSLCTSB | |
| SCHEMBL7735268 | 0.88 | CTSK (0.52) | CTSKSYKCTSSCTSLCTSB | |
| SCHEMBL7397262 | 0.88 | CTSK (0.52) | CTSKSYKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799803-B2 | Hydroxamic acid compounds and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-09-21 | — | — | US | disclosed |
| US-20070155785-A1 | Hydroxamic acid compounds and methods of use thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-07-05 | — | — | US | disclosed |
| US-7199134-B2 | Hydroxamic acid compounds and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-04-03 | — | — | US | disclosed |
| EP-0634998-B1 | HYDROXAMIC ACID BASED COLLAGENASE AND CYTOKINE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 1997-03-19 | — | — | EP | disclosed |
| US-5525629-A | HYDROXAMIC ACID DERIVATIVES | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1996-06-11 | — | — | US | disclosed |
| EP-0634998-A1 | HYDROXAMIC ACID BASED COLLAGENASE AND CYTOKINE INHIBITORS. | BRITISH BIO TECHNOLOGY (GB) | 1995-01-25 | — | — | EP | disclosed |
| WO-1993020047-A1 | HYDROXAMIC ACID BASED COLLAGENASE AND CYTOKINE INHIBITORS | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155785-A1 | Hydroxamic acid compounds and methods of use thereof | HDAC5, BRDT, HDAC1 | CTSK 1702/4885SYK 3209/4885CTSS 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.